CYTK - Cytokinetics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CYTK is currently covered by 17 analysts with an average price target of $56.12. This is a potential upside of $23.99 (74.67%) from yesterday's end of day stock price of $32.13.

Cytokinetics's activity chart (see below) currently has 208 price targets and 242 ratings on display. The stock rating distribution of CYTK is 92.78% BUY and 7.22% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 76.08% with an average time for these price targets to be met of 366.16 days.

Highest price target for CYTK is $120, Lowest price target is $54, average price target is $81.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 02-May-2025. First documented stock forecast 18-Nov-2009.

Currently out of the existing stock ratings of CYTK, 90 are a BUY (92.78%), 7 are a HOLD (7.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

$40.3 (127.13%)

$72

11 days ago
(02-May-2025)

8/20 (40%)

$34.65 (92.77%)

256

Buy

$120

$88.3 (278.55%)

$120

22 days ago
(21-Apr-2025)

38/61 (62.3%)

$82.07 (216.37%)

768

Hold

$54

$22.3 (70.35%)

$60

28 days ago
(15-Apr-2025)

6/8 (75%)

$15.44 (40.04%)

197

Buy

$78

$46.3 (146.06%)

$78

1 months 3 days ago
(10-Apr-2025)

10/18 (55.56%)

$40.15 (106.08%)

410

Buy

$67

$35.3 (111.36%)

$70

3 months ago
(12-Feb-2025)

10/12 (83.33%)

$25.38 (60.98%)

205

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CYTK (Cytokinetics) average time for price targets to be met?

On average it took 366.16 days on average for the stock forecasts to be realized with a an average price target met ratio 76.08

Which analyst has the current highest performing score on CYTK (Cytokinetics) with a proven track record?

AKASH TEWARI

Which analyst has the most public recommendations on CYTK (Cytokinetics)?

Akash Tewari works at JEFFERIES and has 6 price targets and 5 ratings on CYTK

Which analyst is the currently most bullish on CYTK (Cytokinetics)?

Joseph Pantginis with highest potential upside - $88.3

Which analyst is the currently most reserved on CYTK (Cytokinetics)?

Graig Suvannavejh with lowest potential downside - -$31.92

Cytokinetics in the News

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science presentations and one ePoster presentation at Heart Failure 2025, an International Congress of the European Society of Cardiology, taking place in Belgrade, Serbia from May 17, 2025 – May 20, 2025. Late Breaking...

Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Cytokinetics (NASDAQ:CYTK) First Quarter 2025 Results Key Financial Results Revenue: US$1.58m (up 89% from 1Q 2024). Net loss: US$161.4m (loss widened by 19% from 1Q 2024). US$1.36 loss per share (further deteriorated from US$1.33 loss in 1Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.NasdaqGS:CYTK...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?